Spatiotemporal distribution of air pollutants during a heat wave-induced forest fire event in Uttarakhand.

Prevailing dry conditions and rainfall deficit during the spring season in North India led to heat wave conditions which resulted in widespread and intense forest fire events in the Himalayan state of Uttarakhand during April 16-30, 2022. A total of 7589 active fires were detected by VIIRS during the second half of April 2022 compared to 1558 during the first half. The TROPOMI observed total column values of CO and NO2 increased by 4.4% and 11.7%, respectively during April 16-30, 2022 with respect to April 1-15, 2022. A noticeable increase in surface level concentration of trace gases was also observed at Dehradun. In situ measurements of CO, NOx, and O3 during April 16-30, 2022 show an increase of 133, 35, and 6% compared to previous year observations during the same period. Weather Research and Forecasting model with chemistry (WRF-Chem) is utilized to quantitatively estimate the contribution of this event on the distribution of air pollutants over this state. The model results were evaluated against ERA5 reanalysis, upper air soundings, and TROPOMI-retrieved total column density (TCD) of CO, NO2, and O3. Two simulations with (Fire) and without (NoFire) biomass burning emissions input were performed to quantify the contribution of forest fires to the concentration of trace gases and particulates. The CO, NO2, and O3 emitted/produced from forest fire over Uttarakhand during April 2022 contributed approximately 39.95, 35.73, and 9.97% to the surface concentration of respective gas. In the case of aerosols, it was around 71.20, 71.44, and 33.62% for PM2.5, PM10, and BC respectively. The vertical profile analysis of pollutants revealed that extreme forest fire events can perturb the distribution of air pollutants from the surface up to 450 hPa.

Efficacy and tolerability of a ß-1 selective ß blocker, bisoprolol, as a first-line antihypertensive in Indian patients diagnosed with essential hypertension (BRIGHT): an open-label, multicentric observational study.

OBJECTIVES: This study was aimed to evaluate the efficacy and tolerability of bisoprolol, in Indian patients diagnosed with stage I essential hypertension as first-line drug. DESIGN: This was an open-label, phase IV, multicentric prospective study. SETTINGS: 239 outpatient centres across India. PARTICIPANTS: After ethical approval, patients who were willing to sign informed consent, who are newly diagnosed with JNC VII stage I essential hypertension (systolic blood pressure 140-159 mm Hg or diastolic blood pressure 90-99 mm Hg) and who are prescribed bisoprolol were enrolled in the study. Patients with significant organ disease or complications, women of childbearing age refusing reliable contraceptive method, patients with known contraindications (like symptomatic bradycardia, significant atrioventricular blockade, sick sinus syndrome) and patients with known hypersensitivity reactions to bisoprolol and unwilling patients were excluded. PRIMARY AND SECONDARY OUTCOMES MEASURES: The primary outcome measure was percentage of patients achieving blood pressure (BP) ≤140/90 mm Hg at the end of 12 weeks, while multiple secondary outcome measures were assessed. RESULTS: Of 2418 patients screened, 2161 patients were recruited (66.64% men, mean age 51.7±9.8 years, smokers 19.19%) and 2131 (96.44%) patients achieved BP control. There was significant reduction in systolic blood pressure (-25.29; SD: 13.22 mm Hg), diastolic blood pressure (-14.14; SD: 7.67 mm Hg) and heart rate (-12/min; SD: 6.15) compared with baseline (all p values <0.05). The median dose of bisoprolol and average period required for the response were 5 mg/day and 33 days, respectively. Bisoprolol was found to be well tolerated in the patients up to 10 mg/day. A total of 1.9% patients showed adverse events, which were mild to moderate in severity without any severe adverse event. None required treatment withdrawal. CONCLUSION: Bisoprolol is an effective and safe option to control BP. Thus, it can be used as one of the first-line antihypertensive in Indian patients.